Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
Friend
P J
PJ
Department of Surgery, University of Cambridge, Addenbrooke's Hospital, United Kingdom.
Rebello
P
P
Oliveira
D
D
Manna
V
V
Cobbold
S P
SP
Hale
G
G
Jamieson
N V
NV
Jamieson
I
I
Calne
R Y
RY
Harris
D T
DT
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity*; D000917:Antibody Formation; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm; D001379:Azathioprine / Q000627:therapeutic use; D000074301:CD52 Antigen; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006023:Glycoproteins; D006084:Graft Rejection / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine